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Abstract
The cytoskeleton is essential to cell morphology, cargo trafficking, and cell division. As the neuronal cytoskeleton is
extremely complex, it is no wonder that a startling number of neurodegenerative disorders (including but not limited to
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease) share the common feature of a dysfunctional neuronal
cytoskeleton. Recently, concern has been raised about a possible link between anesthesia, post-operative cognitive
dysfunction, and the exacerbation of neurodegenerative disorders. Experimental investigations suggest that anesthetics
bind to and affect cytoskeletal microtubules, and that anesthesia-related cognitive dysfunction involves microtubule
instability, hyper-phosphorylation of the microtubule-associated protein tau, and tau separation from microtubules.
However, exact mechanisms are yet to be identified. In this paper the interaction of anesthetics with the microtubule
subunit protein tubulin is investigated using computer-modeling methods. Homology modeling, molecular dynamics
simulations and surface geometry techniques were used to determine putative binding sites for volatile anesthetics on
tubulin. This was followed by free energy based docking calculations for halothane (2-bromo-2-chloro-1,1,1-trifluoroethane)
on the tubulin body, and C-terminal regions for specific tubulin isotypes. Locations of the putative binding sites, halothane
binding energies and the relation to cytoskeleton function are reported in this paper.
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Introduction
Despite the extensive electrophysiological studies regarding the
effects of inhaled anesthetics on membrane ion channels and
receptor proteins [1–3] the exact molecular mode of action of
anesthetics remains uncertain. In addition to altering the function
of membrane ion channels and receptors in vitro [4–14], the
inhaled anesthetics are known to affect enzymes [15–17] as well as
many cytoplasmic proteins in the mammalian central nervous
system [18–22], providing multiple targets for their actions
including side effects. Among these cytoplasmic proteins is tubulin,
the component protein of cytoskeletal microtubules.
Tubulin proteins polymerize to form microtubules (MTs),
nanoscale cylindrically shaped protein polymers that are part of
the cellular cytoskeleton. The neuronal MT cytoskeleton, in
particular, possesses a unique architecture [23], responsible for
maintaining highly asymmetric neuron morphology and the
intracellular transport of vesicles. Unlike MTs in all other cells,
the MTs in dendrites are interrupted and oriented in local
networks of mixed polarity. Moreover, the ionotropic GABAA
receptor is anchored to the MT cytoskeleton via associated
proteins [24], and an intact MT structure has been shown to be
essential for the activity of GABAA receptors [25]. Likewise, MTs
have been shown to modulate both sodium and calcium current
within neurons [26–30].
A large number of neurological brain disorders bear the
common feature of some kind of disruption to the neuronal
cytoskeleton, particularly MTs, either directly or indirectly
through associated proteins. These include neurodegenerative
disorders such as Alzheimer’s disease, Parkinson’s disease, and
Huntington’s disease [31]. The relation between anesthesia,
postoperative cognitive decline and dementia (in Alzheimer’s
disease and the other neurodegenerative disorders) is uncertain
[32–35]. Anesthesia may exacerbate neurodegeneration, and/or
have its own deleterious effect. Cytoskeletal MTs are a common
link, affected by anesthetics and disrupted in neurodegeneration.
This suggests an important role for the MT cytoskeleton in
anesthetic action, with potential side effects related to post-
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operative cognitive dysfunction. Recently it has been shown that
genetic expression of tubulin is altered following exposure to
desflurane [36], sevoflurane [37], halothane, and isoflurane [38].
LeFreche et al. [39,40] further showed that cognitive dysfunction
following sevoflurane anesthesia was associated with hyper-
phosphorylation of the MT-associated protein (MAP) tau, separa-
tion of tau from MTs, and MT instability, the same signs associated
with neurofibrillary tangles (NFTs) in Alzheimer’s disease. Anes-
thetic binding to tubulin in MTs may be involved in anesthetic
action and toxicity.
Tubulin, a peanut-shaped heterodimer with a and b monomers,
has been identified as a direct binding target for halothane [22].
Additionally, experiment shows volatile anesthetics, particularly
halothane, alter the tubulin self-assembly rates into MTs in
a number of systems, both in vivo [41–46] and in vitro [47], albeit at
extremely high concentrations. When polymerized into MT form,
each tubulin subunit interacts with surrounding dimers, forming
longitudinal contacts between dimers along the protofilament
length, and lateral contacts between protofilaments (see Figure 1).
There also exists an intradimer interaction between the a- and b-
monomers of a single tubulin dimer. In the more prevalent B-
lattice MT formation the lateral contacts are formed between like
subunits (i.e. a-monomer to a-monomer, and b-monomer to b-
monomer on adjacent protofilaments). In the less common A-
lattice, lateral interactions are between a and b monomers.
Volatile anesthetics may inhibit MT assembly dynamics by a direct
molecular interaction between the anesthetic molecule and the
tubulin dimer hindering dimer-dimer, or intradimer interactions.
It is also feasible that volatile anesthetics exert their action on MT
dynamics through an alteration of the local environment affecting
the highly flexible C-terminal tail regions of tubulin. Clearly, the
site and mechanism of anesthetic action on MT assembly and
stability remain to be determined.
Experimental methods to study anesthetic binding to proteins
include NMR spectroscopy, photoaffinity labeling, and site
directed mutagensis. NMR and photoaffinity labeling techniques
can only be applied to purified proteins available in relatively
large quantity. Currently, NMR methods are only capable of
determining the structure of protein complexes with masses up
to 20–30 kDa, which is well below the 110 kDa size of the
tubulin heterodimer, rendering this method not directly
applicable to this problem [48]. Without a priori knowledge of
putative binding sites, site directed mutagenesis is also hindered
by protein size. Direct photoaffinity labeling with halothane
requires combination with methods such as protein digestion
followed by mass spectroscopy to determine binding location,
which also benefits from previously predicted locations to
determine experimental protocols.
Surface geometry techniques used to predict anesthetic
binding sites on proteins are based on static structural data
[49,50]. These methods suffer a general weakness by not
accounting for protein dynamics, neglecting rearrangements of
local protein atoms and the resulting change in binding site
availability. To address these issues we use a combination of
molecular dynamics (MD) and surface geometry based binding
site prediction to identify general putative volatile anesthetic
binding sites on, or in, the tubulin protein. Blind docking
followed site prediction to obtain halothane (2-bromo-2-chloro-
1,1,1-trifluoroethane) binding energy estimates, as the majority
of experiments between volatile anesthetics and tubulin in-
vestigate the interaction with halothane.
Results
Putative Volatile Anesthetic Binding Sites on the Tubulin
Body
A short 5 ns MD simulation was performed on two tubulin
dimers in MT geometry with periodic boundary conditions,
effectively modeling two infinite protofilaments. This 5 ns
simulation is too brief to be representative of the entire
conformational ensemble. However, it does serve to allow side
chain motion while keeping the protein backbone of the structure
relatively stable (see Figure 2).
Clustering of the 5 ns MD simulation trajectories resulted in 11
distinct protein conformations, with each cluster containing several
snapshots of the protein at different time steps. Taking each
snapshot in a cluster to be represented by the average
conformation of the cluster resulted in the 11 dominant
conformations existing for various portions of the simulation (see
Table 1). Since each dominant conformation is represented by the
average conformation of several snapshots at different timesteps,
a given dominant conformation represents a certain percentage of
the MD simulation (see Table 1 - % Simulation).
A modified PASS algorithm [51] was performed on each of the
dominant conformations for both dimers in MT protofilament
geometry, and for each dimer separately. PASS predicts putative
Figure 1. Tubulin in MT formation. (A) Tubulin dimer. Light grey –a-tubulin, Dark Grey – b-tubulin. C-terminal tails extend from the main tubulin
body. (B) B-lattice MT with protofilament highlighted. (C) Tubulin interactions in MT formation. Intradimer – between a- and b-tubulins, Longitudinal
– between dimers in a protofilament, Lateral – between protofilaments.
doi:10.1371/journal.pone.0037251.g001
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binding sites (hydrophobic crevices and pockets) through an
iterative coating of the protein surface with probe spheres.
Potential sites are based on the burial depth of these spheres.
Modification of this algorithm to additionally measure for
hydrophobicity yields efficient prediction of volatile anesthetic
binding sites [49]. This procedure yielded numerous putative
anesthetic-binding sites on tubulin, which would be valid for any
volatile anesthetic.
Due to the motion of side chains the predicted sites varied
between the different protein conformations. The DBSCAN
method [52] spatially grouped the predicted sites yielding 47
unique potential binding sites on the tubulin protein, however
some sites were not found in all of the conformations. As such,
each site was assigned a persistence value denoting the percentage
of the MD simulation in which the potential binding site was
found. The persistence of each site was calculated by taking the
sum of the simulation percentages (see Table 1 - % Simulation) for
each of the dominant conformations on which the site was
predicted (e.g. If a site was found for dominant tubulin
conformation 1, 2, and 3, the persistence would be 5.18% +
0.80% + 11.55% = 17.53% of the MD simulation). Persistence
values varied greatly from 0.80% to 100% of the 5 ns simulation
(see Table 2 and 3). Of the 47 predicted sites, 9 persisted for more
than 70% of the simulation, and of these 5 persisted for the entire
simulation (see Figure 3).
Halothane Docking
Tubulin body. Focused docking of a halothane molecule (see
Figure 4) at each of the predicted putative volatile anesthetic
binding sites on each of the tubulin clusters yielded varying
binding energies between clusters for a given site. The binding
mode with the lowest binding energy value for a given site was
taken, generally resulting in one binding mode whose binding
energy is listed in Table 2. In the case of multiple binding modes,
the binding energy of the largest cluster was taken. Examination of
the energy contributions yielded binding due mainly to van der
Waals interactions with the Cl and Br atoms generally contrib-
uting the largest portion. Other energy contributions served to
weaken this interaction.
C-terminal tails. For each tubulin isotype found in the
brain, 50 distinct conformations of the C-terminal tail regions
were generated sampling the tail conformational space (see
Figure 2. Plot of protein backbone RMSD over 5 ns simulation.
doi:10.1371/journal.pone.0037251.g002
Table 1. Percent of simulation for the dominant tubulin
conformations.
Tubulin
Conformation
Timesteps
(out of 251) Simulation % Rank
1 13 5.18 6
2 2 0.80 2
3 29 11.55 4
4 9 3.59 7
5 57 22.71 2
6 32 12.75 3
7 69 27.49 1
8 4 1.59 8
9 13 5.18 6
10 19 7.57 5
11 4 1.59 8
doi:10.1371/journal.pone.0037251.t001
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Figure 5). Blind docking of the halothane molecule to each of
the tail conformations resulted in various binding locations and
in poses dependent on the sequence of the tail, as well as the
specific tail conformation. The range of halothane binding
energies for each of the tubulin isotypes is given in Table 4.
The energy contributions yielded binding due mainly to van der
Waals interactions again with the Cl and Br atoms contributing
the largest portion. In general, binding energies increased with
the number of available surrounding residues. Thus, tail
conformations, which were compacted, forming loops or coils,
provided more favorable binding conditions. Binding energies
for these ideal binding-conditions were comparable to binding
on the tubulin body.
Microtubule Polymerization Assay
Multiple polymerization assays were run for tubulin alone
(control), tubulin with 10 mM paclitaxel, tubulin with 40 mM
halothane, and tubulin with both 10 mM paclitaxel and 40 mM
halothane (see Figure 6). A 40 mM halothane concentration was
used to ensure interaction of halothane with tubulin. The
control run showed optical density results consistent with
normal tubulin polymerization. In the presence of 10 mM
paclitaxel optical density increases sharply and falling off in the
longer time limit. This is consistent with normal results obtained
from mist experiment with quick polymerization showing the
stabilizing effect of paclitaxel. In the presence of both 10 mM
paclitaxel and 40 mM halothane the optical density curve is
Table 2. Persistence, surrounding residues, and halothane binding energies of putative volatile anesthetic binding sites on a single
ab-tubulin dimer.
Site
Persistence
(Simulation %) Residues within 5 A˚a Energy (kcal/mol)
a-tubulin
23 100.00 aQ11, aA12 22.54
8 51.00 aI188, aA421, aD424, aM425, aA426, aA427, aL428 22.70
20 43.82 aG321, aP359, aP360, aT361, aV362, aV371, aQ372 22.91
32 27.49 aY103, aY408, aE417, aF418 23.39
25 21.51 aV62, aP63, aV66, aF67, aF87, aH88, aP89, aE90, aQ91 23.31
2 20.32 aL23, aN228, aR229, aQ233, aP364 22.67
27 11.55 aR123, aL132, aD160 22.17
26 11.55 aS6, aH8, aC20, aR64, aA65, aL136, aV235, aS236 22.90
3 6.77 aN216, aP274, aI276, aQ285, aL286, aI291, aN300 22.46
22 5.18 aH107, aY108, aI115, aL152, aL153, aR156 22.60
19 5.18 aV288, aA289, aV324, aK326, aD327 22.10
29 3.59 aT292, aN293, aD327, aA330, aA331, aA334 22.45
33 1.59 aH266, aM313, aA314, aN380, aT382, aY432 22.89
35 1.59 aA174, aP175, aM203, aV204, aD205, aL269, aV303, aI384 22.77
13 1.59 aG310, aM313, aT382, aA385, aE433 22.52
24 0.80 aF202, aV204, aI209, aL230, aI231, aI234, aY272, aM302, aV303 23.17
b-tubulin
4 100.00 bV295, bF296, bV315, bA316, bA317, bM332 23.12
21 100.00 bV171, bI204, bN206, bY210, bY224, bV231 22.85
7 78.88 bT240, bC241, bL248, bN249, bA354, bV355 23.13
1 70.12 bC12, bV171, bV172, bP173, bV177, bD179 23.04
12 34.26 bY108, bV115, bL152, bL153, bK156, bI157 22.99
30 31.87 bA208, bR215, bM301, bM302, bA304 22.73
10 27.09 bL219, bT221, bP222, bT223, bL227, bL230 22.68
18 23.51 bS117, bD120 22.66
17 21.91 bV172, bP173, bS174, bP175, bC203, bD205, bA303, bL387, bI391 22.89
34 15.94 bL313, bT314, bP348, bN350, bV351, bK352 22.81
9 12.75 bR284, bL286, bT287, bL291, bK372, bM373 22.79
6 11.55 bL119, bD120, bV122, bR123, bI157 22.20
31 9.16 bA298, bK299, bM301, bM302, bA303, bA304 22.85
16 7.57 bR123, bA126, bL132, bQ133, bF135, bY161, bR164 22.52
11 1.59 bI31, bT33, bK60, bY61, bV62 22.50
15 1.59 bL119, bD120, bV122, bR123, bF135, bI157 22.48
aResidues are numbered according to the scheme of Lo¨we et al. [61].
doi:10.1371/journal.pone.0037251.t002
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comparable to that of paclitaxel alone within standard error.
This indicates that halothane has no effect on the interaction
between paclitaxel and tubulin. In the presence of 40 mM
halothane alone the optical density curve resembles the control
situation, however the standard error indicates difference
between the curves with a small increase in the optical density.
Discussion
Interaction Mechanisms
The average brain volume is 1.4 L. Assuming approximately
109 tubulin dimers per neuron, with 1011 neurons per brain, the
average concentration of tubulin protein in the brain is 120 mM.
However, in the neuron this may be 2–3 times higher since glial
cells, possessing a MT density much less than neurons, are
considered to comprise 50% of the brain. The remaining portion
is composed of both neurons and other necessary structures such
Table 3. Persistence, surrounding residues, and halothane binding energies of putative volatile anesthetic binding sites at tubulin
interfaces.
Site
Persistence
(Simulation %) Residues within 5 A˚a
HalothaneBinding
Energy (kcal/mol)
Intradimer
5 100.00 aQ11, aA12, aI171, aV177, aS178, aT179 / bQ247 22.74
37 100.00 aM398 / bN258, bP261, bL313 22.76
38 84.06 aA180, aV181/ bK254, bV257, bT314 22.72
41 56.18 aF404 / bI165, bD199, bA256, bV257, bV260 22.52
44 22.71 aT223 / bS324, bA354, bV355, bC356, bD357 22.29
14 12.75 aH406 / bE196, bN197, bT198, bL273 22.62
46 7.57 aQ176, aS178, aA180, aV181 / bK352 22.62
40 0.80 aP184, aR390, aL391 / bI347 22.52
Longitudinal
39 88.05 aL242, aA247, aV250 / bQ13, bT145, bD179 22.44
Lateral - a-tubulins
43 26.29 aI212, aN216, aA273, aP274, aV275, aL286, aE290, aI291, aN300 / aK124 22.33
36 19.52 aH283, aS287, aE290 / aE55, aV62, aE90 22.68
Lateral - b-tubulins
28 40.24 bD90, bV93, bF94 / bT252 22.69
47 40.24 bS128 / bV288, bP289, bE327, bQ331 22.35
45 7.57 bV62, bF87, bR88 / bT287, bV288, bM373 22.84
42 0.80 bD90 / bI212, bR215, bT216, bL217, bP274, bK299 22.69
aResidues are numbered according to the scheme of Lo¨we et al. [61].
doi:10.1371/journal.pone.0037251.t003
Figure 3. Putative volatile anesthetic binding sites on the tubulin body. (A) 47 total sites (red spheres) with persistence ranging from 0.80%
to 100%. (B) 9 most persistent, and probable, sites (orange spheres), with persistence of 70% or greater.
doi:10.1371/journal.pone.0037251.g003
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as ventricles, blood vessels etc. Comparing an assumed total
neuronal tubulin protein concentration of 240–360 mM, to
a halothane concentration of 250–500 mM (,1 to 2 MAC) gives
1 to 2 halothane molecules per tubulin dimer at clinically relevant
concentrations. However, occupancy depends not on equilibrated
concentrations of protein and drug alone, but rather drug
concentration and dissociation constant. The halothane binding
energies suggest Kd values between 6 and 16 mM. This yields
a fractional occupancy of 1%–8% at 1 to 2 MAC, assuming the
system is equilibrated. However, this does not account for the non-
equilibrium state of biological systems, nor does it account for
multiple affinity sites or sites of partial binding.
The existence of many sites with similar binding energies made
it difficult to assign binding to any particular site(s). In fact, it is
likely that anesthetics bind non-specifically to many of the
predicted binding sites. Low persistence of a binding site does
not necessarily indicate that a potential site is invalid. Rather, it
implies a lack of favorable conditions for binding, since these sites
are associated with greater overall conformational free energies of
the protein system. However, anesthetic molecules may bind to
low persistence sites, potentially with a greater binding energy than
to higher persistence sites. In light of this, it is expected that at
a constant anesthetic concentration, the sites that are most
occupied are determined by the sum of the conformational energy
differences, as reflected in persistence, and binding free energy
differences.
A total of 32 binding sites (16 on a-tubulin, and 16 on b-tubulin)
were predicted on a single tubulin dimer, which were independent
Figure 4. Halothane molecule structure parameters. (A) Bond
lengths in A˚. (B) Bond (dashed), and dihedral (solid) angles in degrees.
Parameters obtained from an ab initio structure calculation [108].
doi:10.1371/journal.pone.0037251.g004
Figure 5. Representative halothane binding modes on the
TUBB2B C-terminal tail. Red – N-terminal end connecting to the
main tubulin body (body not shown for clarity), Blue – C-terminus. (A)
21.68 kcal/mol, (B) 22.3 kcal/mol, and (C) 22.79 kcal/mol.
doi:10.1371/journal.pone.0037251.g005
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of the dimer placement in MT geometry (see Table 2). Only one of
the sites predicted on a-tubulin (site 23) persisted for more than
70% of the simulation, in fact lasting for the entirety of the
simulation. Four sites predicted on b-tubulin (sites 1, 4, 7 and 21)
lasted for more than 70% of the simulation, with two sites (4 and
21) lasting the entire simulation. An additional 8 sites were located
at the intradimer a-b interface (see Table 3). These also did not
depend on the placement of the dimer within the MT structure.
Site 38 persisted in this region for 84.06% of the simulation, while
sites 5 and 37 lasted for 100% of the time. Seven sites were
dependent on the placement of the dimers within the MT lattice
(see Table 3). One site was predicted at the dimer-dimer interface
lasting for 88.05% of the simulation. The remaining 6 sites were
located at the protofilament interfaces, either between a- or b-
tubulins, however all of these persisted for less than 50% of the
simulation. Reasonable anesthetic concentrations may thus alter
only longitudinal, or intradimer interactions, but only at
sufficiently high concentrations would lateral attraction be
affected.
Binding energy estimates for halothane with the tubulin C-
terminal tails are comparable to binding on the main protein body
suggesting another mode of interaction. Larger binding energies
exist for more compact conformations of the C-terminal tail. As
such, due to the flexibility of the C-terminal tails, interaction with
halothane may sequester the tail region, holding them in more
compact forms, and preventing normal tail movements. This is of
importance to the function of MTs as evidence indicates the C-
termini play critical roles in regulating microtubule structure,
function and interaction with MAPs [53–60]. Sequestration of the
C-terminal tails by halothane into compact forms may indeed alter
tubulin polymerization dynamics.
Comparison to Known Drug Binding Sites
Taxol. Taxol is a MT-stabilizing agent that makes direct
contact with a substantial number of the b-tubulin residues upon
binding. The taxol-binding pocket is defined by the b-tubulin H1
helix (including bV23 and bD26), H6–H7 loop (including bL217
and bL219), H7 helix (including bH229, bL230, bA233 and
bS236), M loop between strand S7 and helix H9 (including bF272,
bP274, bL275, bT276, bS277 and bR278), and the S9–S10 loop
(including bP360, bR369, bQ370 and bL371) [61]. Taxol acts to
stabilize the M-loop increasing inter-protofilament interactions.
Of the key residues, anesthetic site 10 is within 5 A˚ of bL219,
and site 42 is within 5 A˚ of bL217 and bP274. bP274 forms part of
the hydrophobic pocket for the taxol 39-phenyl group, while
bL217 makes hydrophobic contact with the 2-phenyl ring of taxol,
a component of taxol shown to be absolutely required for its
activity [62]. bL219 also makes hydrophobic contact with the 2-
phenyl ring.
Interaction of volatile anesthetics in this region may alter taxol
binding resulting in loss of function. However, site 42 is negligibly
persistent, only lasting for 0.80 % of the simulation, and site 10
persists minimally for ,27% of the simulation. Therefore, this
behavior would only be expected in cases of high anesthetic
concentrations.
The tubulin polymerization experiment suggests that this is
indeed the case. Tubulin in the presence of 10 mM of paclitaxel
produced similar optical density curves over time in both the
presence and absence of 40 mM concentration of halothane.
Thus, halothane does not affect the interaction of taxol with
tubulin consistent with the computational prediction.
Colchicine. Colchicine inhibits MT polymerization by bind-
ing to free tubulin dimers at the intradimer interface and
interacting with both a- and b-tubulin residues. The colchicine
site is mainly located within the b-tubulin, and is surrounded by
residues bC241, the b-tubulin T7 loop, H8 helix (including
bD251), S8 strand (including bV318), and S9 strand (including
bK352), and interacts with residues aE71, aN101, and the a-
tubulin T5 loop (including aV181) [63].
Steric hindrance between aV181 and colchicine prevents the a-
tubulin subunit from occupying its normal position interfering with
the straight conformation adopted by tubulin in protofilaments.
The loss of this straight conformation prevents the tubulin M-loop
from establishing lateral contacts between protofilament ends,
leading to hindrance of MT dynamics and eventually MT
depolymerization (or lack of MT polymerization from free
tubulin). Additionally, binding of colchicine requires movement
of the b-tubulin T7 loop and H8 helix to accommodate the drug
molecule, and this movement also interferes with the a-b in-
teraction.
Site 38 is within 5 A˚ of residue aV181, of the a-tubulin T5 loop,
and the b-tubulin H8 helix and S8 strand, and persists for
a considerable 84.06% of the simulation. Site 7 is located within
5 A˚ of residue bC241, and the b-tubulin T7 loop and S9 strand
and persists for 78.88 %, while site 41 persists for 56.18% and is
located within 5 A˚ of the b-tubulin H8 loop. Site 34 is located
within 5 A˚ of the b-tubulin S8 and S9 strands including residue
bK352, and site 46 is within 5 A˚ distance of the a-tubulin T5 loop,
Table 4. Tubulin isotype, sequence and halothane binding energy range for the C-terminal tail regions found in the brain.
Tubulin Isotype C-terminal tail sequencea Halothane Binding Energy Range (kcal/mol)
a-tubulin
TUBA1A DYEEVGVDSVEGEEEGEEY 21.89 to 22.95
TUBA1C DYEEVGADSADGEDEGEEY 21.75 to 22.57
TUBA4A DYEEVGIDSYEDEDEGEE 21.86 to 22.78
b-tubulin
TUBB DATAEEEEDFGEEAEEEA 21.60 to 22.82
TUBB2A / TUBB2B DATADEQGEFEEEEGEDEA 21.68 to 22.79
TUBB2C DATAEEEGEFEEEAEEEVA 21.62 to 23.12
TUBB3 DATAEEEGEMYEDDEEESEAQGPK 21.63 to 22.81
TUBB4 DATAEQGEFEEEAEEEVA 21.63 to 23.00
aAdapted from Luduena et al. [94].
doi:10.1371/journal.pone.0037251.t004
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including residue aV181, and bK352 of the b-tubulin S9 strand,
however they persist minimally for less than 20% of the
simulation.
The preferred binding mode of halothane at site 38 was shown
to occupy a space surrounded by helix bH8 and strand bS8, while
the binding mode at site 7 is within 3 A˚ of bC241 and surrounded
by helix bH8 and strand bS9 (see Figure 7). Van der Waals
interaction of halothane with the bH8 helix would reduce the
mobility of these residues preventing the accommodation of the
colchicine molecule in this pocket. This is consistent with findings
that report a reduction in colchicine binding to tubulin in the
presence of halothane [64].
Interaction of volatile anesthetics with the b-tubulin T7 loop or
H8 helix can reduce the mobility of these regions preventing the
movement required to accommodate the colchicine molecule
within tubulin. Additionally, interaction of volatile anesthetics with
residue aV181 can hinder the movement of the a-tubulin T5 loop
produced by the steric clash with colchicine. As these sites are
persistent it is thus expected that volatile anesthetics would hinder
the binding of colchicine. The effect of volatile anesthetics on the
binding of colchicine derivatives must also be considered as it is
known that colchicine derivatives substituted at the methoxy
positions of ring A can be cross-linked with bC241 and anesthetics
at site 7 may reduce this interaction.
Vinblastine. Vinblastine is one of the vinca alkaloids and is
an inhibitor of tubulin polymerization. The primary binding site of
vinblastine is located at the MT plus (growing) end towards the
inner lumen of the MT and works by inhibiting longitudinal
(dimer-dimer) contacts in a protofilament. The vinblastine
binding-pocket is boxed by the a-tubulin T7 loop (including
aL248 and aN249), H10 helix and S9 strand (including aL352),
and the b-tubulin T5 loop (including bV177 and bD179), H6 helix
carboxy-terminal turn (including bY210), and the loop region
between helices H6 and H7 (including bF214) [65]. Vinblastine
affecting these regions alters the longitudinal interface between
tubulin dimers constraining them in a curved assembly to avoid
steric clashes with the drug molecule. The curvature induces
displacement of the M-loop on subsequent dimers weakening
lateral interactions leading to reduced MT dynamics and eventual
MT depolymerization.
Site 21, which persists for the entirety of the simulation, is within
5 A˚ of bY210 in the carboxy-terminal turn of helix H6. Site 39,
which persists for 88.05% of the simulation, and site 1, which
persists for 70.12% of the simulation, neighbor residue bD179.
Site 1 is also adjacent to bV177. Interaction of volatile anesthetics
with these residues is expected to alter vinblastine binding either
through competitive binding, or hindrance of the mobility
required to avoid steric clashes. Sites 19 and 20 are in the region
of the a-tubulin H10 helix, and sites 17 and 42 are within the b-
tubulin H6 helix and H6–H7 loop regions. However, these sites all
exhibit low persistence.
The effect of volatile anesthetics on derivatives of vinorelbine,
a vinblastine analogue modified on the D’ ring, should also be
considered. Changes in these derivatives, which yield modified
affinities and activities, occur in regions that interact with bY224
[66], a residue within distance of site 21.
Halothane binding in the vinblastine pocket is shown in
Figure 8. The binding mode of halothane at site 21 is within
2 A˚ of bY210 and the molecule is surrounded by helices bH6 and
Figure 6. Microtubule polymerization assays. Black circle – General Tubulin Buffer (80 mM PIPES, MgCl2, 0.5 mM EGTA, pH 6.9). Green triangle –
General Tubulin Buffer + 40 mM halothane. Blue square – General Tubulin Buffer + 10 mM paclitaxel. Red diamond – General Tubulin Buffer + 10 mM
paclitaxel + 40 mM halothane. Mean values and standard deviation shown.
doi:10.1371/journal.pone.0037251.g006
Figure 7. Halothane binding in the colchicine-binding pocket.
Blue – loop aT5, Red - strand bS9, Yellow – loop bT7 and helix bH8,
Green – strand bS8, Orange – aE71, aN101, and bC241. (A) Colchicine
binding site. (B) Halothane binding site 38, -2.72 kcal/mol, surrounded
helix bH8 and strand bS8. (C) Halothane binding site 7, -3.13 kcal/mol,
within 3 A˚ of bC241 and surrounded by strand bS9 and loop bT7.
doi:10.1371/journal.pone.0037251.g007
Anesthetic Interactions with the MT Cytoskeleton
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e37251
bH7. Halothane binding at site 39 is within 5 A˚ of aK352 and
bD179 and is cradled by the surrounding aT7 loop. Halothane at
site 1 lies within 3 A˚ of bD177 and is surrounded on each side by
loops bT5 and bT4. Due to the van der Waals interaction
halothane can alter the mobility of these regions key to vinblastine
binding potentially reducing vinblastine binding.
One point of interest is that vinblastine and colchicine are
known to inhibit assembly at intermediate concentrations while
inducing MT-to-macrotubule transformations at high concentra-
tions [67–69]. Indeed it has been shown that halothane and other
volatile anesthetics may induce the same aberrant forms of tubulin
polymerization, albeit at extremely high concentrations
[43,44,70]. Preferential binding of halothane to a less stable
conformation of the vinblastine or colchicine cavity may result in
destabilization of the longitudinal interaction resulting in an effect
similar to that of these antimitotic drugs.
Peloruside A. The macrolide peloruside A is a MT-stabiliz-
ing agent that synergizes with taxoid drugs by acting at a unique
site. The proposed peloruside A binding site is located on the
exterior of the b-tubulin and is defined by the H9 helix (including
bQ294), the H9–H9’ loop (including bD297 and bR308), the H9’
helix, the H9’-S9 loop, portions of strand S8, and the H10 helix
(including bV335, bN339 and bY342) [71]. It is suggested that
peloruside A stabilizes protofilament interactions by securing the
a-tubulin T5 loop with the adjacent residues found in the b-
tubulin H9–H9’ loop, the H9’ helix, and the H9’-S8 loop,
although the exact mechanism is not known.
Site 4 contacts the H9 helix, the H9–H9’ loop, the H9’ helix
and the H9’-S8 loop and persists for 100% of the simulation.
Additionally site 37 and site 38 contact the H9’ helix and H9’-S8
loop, and persist for 100% and 84.06% of the simulation,
respectively. While the exact mechanism by which peloruside A
acts is unknown, it can be expected that volatile anesthetics in this
binding- region would alter both drug binding, and the resulting
conformational changes which yield its stabilizing effect at
reasonable anesthetic concentrations.
Sites 9, 17, 30, 31, 34 and 42 are all within this region as well,
however their persistence is low. At high anesthetic concentration
it is expected that the multitude of potential sites in this region
would alter the effects of peloruside A significantly.
Laulimalide. Laulimalide is a potent, macrolide MT-stabi-
lizing agent that binds to the exterior of the MT on b-tubulin near
the C-terminal E-hook. The binding site, which encompasses the
proposed peloruside A pocket, is surrounded by the b-tubulin H9–
H9’ loop (including bF296), H9’ helix (including bR308), H10
helix (including bV335) and the H10–S8 loop (including bN339
Figure 8. Halothane binding in the vinblastine-binding pocket. Red - loop aT7, Yellow – helix aH10, Green – strand aS9, Blue – loop bT5,
Orange – helix bH6 and loop bH6-bH7. (A) Vinblastine binding site. (B) Halothane binding at site 21, 22.85 kcal/mol, within 2 A˚ of bY210 and
surrounded by bH6 and bH7. (C) Halothane binding at site 39, 22.44 kcal/mol, within 5 A˚ of aK352 and bD179. (D) Halothane binding at site 1,
23.04 kcal/mol, within 3 A˚ of bD177 and surrounded by bT5.
doi:10.1371/journal.pone.0037251.g008
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and bY342) [72]. Laulimalide does not appear to bind to the a-
tubulin.
Upon laulimalide binding both bR308 and bY342 reorganize to
generate a cation-p interaction, increasing the stabilization of the
loops in this pocket. In this configuration bR306 establishes polar
contacts with the oxygen of the dihydropyran, in the laulimalide
side chain. The hydrophobic bV335 and bF296 residues also
reorganize to align in parallel with the laulimalide macrolactone
ring, with the movement of bF296 creating an entrance into a deep
cavity in b-tubulin. Finally, the bN337 residue, which also defines
this cavity, forms a hydrogen bond with the hydroxyl group at
laulimalide C15.
As with peloruside A, Site 4, 37 and 38 persist in this region
for a considerable portion of the simulation suggesting that
volatile anesthetics binding in this region would alter both drug
binding, and the resulting conformational changes. Sites 9, 17,
30, 31, 34 and 42, again, would be expected to play a role only
at high anesthetic concentration. One key point of interest is
that site 4 is within 5 A˚ of bF296. Reduced mobility of this
residue, by interaction with an anesthetic molecule, is expected
to inhibit binding of the laulimalide molecule through unfavor-
able alignment of bF296 with the laulimalide macrolactone ring
and subsequent shrinkage of the deep cavity entrance.
Additionally, even though laulimalide may possess a greater
binding affinity for tubulin than the volatile anesthetics, small
anesthetic molecules occupying the deep cavity region may be
prevented from escaping by an impinging laulimalide molecule.
This would result in a binding ‘‘stalemate’’ preventing proper
laulimalide effects.
Comparison to Nucleotide Binding Sites
Non-exchangeable GTP. a- and b- tubulin each bind one
molecule of GTP (or GDP). GTP bound to the a-tubulin, at the N-
site, is non-exchangeable and cannot be hydrolyzed to GDP. The
N-site is located at the intra-dimer interface and is characterized
by the a-tubulin H1 helix (including aG10, aQ11, aA12, aQ15,
and aI16), T2 loop (including aD69, aL70 and aE71), H2 helix
(including aV74), T3 loop (including aA99, aA100, and aN101),
T4 loop (including aS140, aF141, aG142, aG143, aG144, aT145
and aG146), T5 loop (including aI171, aY172, aP173, aA174,
aT179, aA180 and aE183), aN206 of the T6 loop, and H7 helix
(including aY224, aL227, aN228 and aI231), as well as the b-
tubulin T7 loop (including bL248 and bN249), bK254 of the H8
helix, and bK352 of the S9 strand [61].
Site 5, 23, 38 and 7 all persist for a significant portion of the
simulation (100%, 100%, 74.06% and 78.88%, respectively),
and all neighbor residues that directly interact with either GTP
or the magnesium ion (Mg2+) required for the intradimer a-
b stability. Sites 2, 24, 34, 35, and 46 are also in this same
region, but persist for less than 21% of the simulation.
Anesthetics at these sites may interfere with interactions between
GTP, Mg2+, and tubulin. The effect of volatile anesthetics on
GTP binding has not been studied for tubulin, but it has been
found that volatile agents, at clinically relevant doses, have
a direct effect on the conformation and stability of the GTP/
Mg2+ bound state of some, but not all, GTP binding proteins
[73]. This indicates the possibility of volatile anesthetics altering
GTP dependent MT dynamics resulting in reduced polymeri-
zation, however further investigation is needed.
Also of note, site 5 borders residues aI171 and aT179, and site
38 is adjacent to residue aA180, which are all part of the sugar
binding T5 loop. These residues are involved in longitudinal
contacts between dimers, and the lateral, protofilament, interac-
tions. This suggests a possible anesthetic induced MT depolymer-
ization mechanism.
Exchangeable GTP. GTP bound to the b-tubulin, at the E-
site, is exchangeable and can be hydrolyzed to GDP. GTP is
required at the E-site in order for tubulin to polymerize, but is
hydrolyzed to GDP upon polymerization. The result is a meta-
stable MT structure stabilized by a so-called cap of remaining
GTP-tubulin subunits. The loss of this cap results in rapid
depolymerization.
The E-site is located at the inter-dimer interface and is
characterized by the b-tubulin H1 helix (including bG10, bQ11,
bC12, bQ15, and bI16), T2 loop (including bD69, bL70 and
bE71), H2 helix (including bT74), T3 loop (including bA99,
bG100, and bN101), T4 loop (including bS140, bL141, bG142,
bG143, bG144, bT145 and bG146), T5 loop (including bV171,
bV172, bP173, bS174, bD179, bT180 and bE183), bN206 of the
T6 loop, and H7 helix (including bY224, bL227, bN228 and
bV231), as well as the a-tubulin T7 loop (including aL248 and
aN249), aE254 of the H8 helix, and aK352 of the S9 strand [61].
Sites 1, 21 and 39 all persist for a significant portion of the
simulation (70.12%, 100%, and 88.05%, respectively), and all
neighbor residues that directly interact with either GTP or the
magnesium ion (Mg2+) in the non-hydrolyzed state, or with GDP
in the hydrolyzed state. Sites 10 and 17 also make contact with key
residues, but persist for less than 28% of the simulation. This
indicates a potential for volatile anesthetics to affect GTP
dependent polymerization dynamics as discussed above.
Similar to the N-site, sites 1, 21 and 39 neighbor residues in the
T5 loop, potentially affecting lateral interactions between proto-
filaments. Additionally, site 21 encompasses bN206. Tubulin’s
preference for GTP is the result of hydrogen bonding of the 2-
exocyclic amino group in GTP to the hydroxyl groups of the N206
and N228 residues, and by hydrogen bonding of the 6-oxo group
to the amino group of N206 [61]. Interactions of anesthetics with
bN206 at the E-site could potentially reduce tubulin’s specificity
for GTP hampering the stabilizing nature of the GTP cap
resulting in increased depolymerization events.
Comparison to MAP-binding Sites
MAPs bind to polymerized tubulin to regulate MT dynamics.
The numerous MAPs identified carry out a wide range of
functions dependent on the host tissue in which they are found.
These functions include stabilizing and destabilizing MTs, guiding
MT transport, cross-linking of MTs, and mediating interactions
between MTs and other proteins or membranes. In the neuron
MAP1A, MAP1B, MAP2 and tau are the most prominent MAPs,
and all serve to stabilize MTs.
The exact binding location of these MAPs on tubulin is not
known. However, it is known that MAP2 and tau share a sequence
similarity in their MT binding repeats close to their carboxyl ends
[74,75]. The proline-glycine-glycine-glycine (PGGG) motifs, be-
lieved to form tight turns upon association with MTs, are
analogous to a sequence in the S9–S10 loop of a-tubulin (residues
T361–L368), which fills the equivalent of the taxol site in the a-
tubulin stabilizing the M-loop conformation [76,77]. It is believed
that MAPs occupy the taxol-binding region in the b-tubulin
securing the M-loop and stabilizing MTs in a manner similar to
the action of taxol.
As discussed above, interactions of volatile anesthetics with MTs
are not expected to alter the effect of taxol except at high
anesthetic concentration. This can be extended to include MAPs
acting by the same mechanism. The effect of volatile anesthetics
on other MAP binding modes is unknown.
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Comparison to Post-translational Modification Sites
In animals, tubulin may undergo numerous post-translational
modifications involved in regulating MT stability and the in-
teraction with MAPs. The a-tubulin may undergo acetylation,
tyrosinolation/detyrosinolation, deglutamylation, palimotoylation,
polyglutamylation polyglycylation, and phosphorylation whereas
the b-tubulin may only undergo the latter three [78]. The majority
of these modifications, including tyrosinolation/detyrosinolation,
deglutamylation, polyglutamylation, and polyglycylation, occur in
the C-terminal region of tubulin.
Post-translational modifications require enzymes to interact
with the C-terminal region, and it is expected that this process
would require the tails to exhibit normal flexibility. The
interaction of halothane with the C-terminal tails indicates an
increase in binding energy with the number of residues interacting
with the molecule. Halothane may thus serve to reduce the motion
of these tail regions interfering with normal post-translation
modification processes.
Acetylation of a-tubulin takes place at the e-amino group of
aK40. Palimotoylation occurs on a-tubulin C376. No predicted
volatile anesthetic sites reside near these locations.
Phosphorylation takes place on both a- and b-tubulin at
tyrosine residues, or serine/ threonine residues on after residue
307 [79]. Several predicted sites reside near serine or threonine
residues in this region, or near tyrosine residues, but the majority
of these sites persist for less than 50% of the simulation. However,
site 38, persisting for 84.06% of the time, is within 5 A˚ of bT314.
Additionally, site 21, which lasts for the entire simulation, is within
5 A˚ of both bY210 and bY224. This indicates a potential
interference of volatile anesthetics with tubulin phosphorylation,
yet the exact location of this modification is not known. This is of
interest as tubulin phosphorylation has been suggested as
a molecular mechanism for memory encoding [80,81].
Comparison to Zinc Binding Sites
In regards to Alzheimer’s Disease, zinc has been shown to
promote the aggregation of b-amyloid, which then sequesters the
metal making it largely unavailable, causing zinc dyshomeostasis in
the vicinity of b-amyloid deposits [82]. While b-amyloid plaques
are necessary to initiate the neurodegenerative process in AD, it is
the NFTs that lead to neurodegeneration. Recently it has been
argued that zinc sequestration by b-amyloid deposits deplete intra-
neuronal zinc which drives formation of NFT, MT destabilization
and associated neuronal degeneration [83]. The study, which
investigates zinc binding to MTs and their component tubulin
proteins, predicts 6 zinc-binding sites under the highest stringency.
Cysteine, histidine, aspartic acid and glutamic acid amino acid
residues are key to zinc binding and account for ,97% of all zinc-
binding amino acids [84]. The 6 predicted binding sites and key
residues involved include the site associated with zinc-induced
tubulin sheet formation (including aH192, aE420 and aD424)
[61], a site near the non-exchangeable GTP site, an uncharacter-
ized site on the a-tubulin (including aH266 and aD431), a site
near the colchicine binding site (including bC243, bC356 and
bD357), and two uncharacterized sites on the b-tubulin.
Site 33 neighbors the aH266 and aD431 residues of the
uncharacterized a-tubulin site, but persists for a mere 1.59% of the
simulation, indicating that volatile anesthetic interactions with zinc
bound at this site are not expected to play a significant role unless
high anesthetic concentrations are used. Site 8, which persists for
51% of the simulation, is within 5 A˚ of aD424 of the zinc-induced
tubulin sheet formation site. This site is only expected to play a role
in tubulin polymerization at zinc concentrations well above
physiological conditions, however the zinc-binding site near the
colchicine site is expected to play a significant role in tubulin
polymerization at physiological zinc concentrations [83]. Site 7,
and 44 border on the colchicine zinc-binding site. Site 7, which
persists for 78.88%, is near bC241, while site 44, which persists for
22.71%, is adjacent to bC356 and bD357. Due to their large
dipole moments, the presence of a volatile anesthetic in these
regions is expected to interfere with van der Waals forces required
for the residue coordination necessary for zinc binding. Should this
occur volatile anesthetics would temporarily inhibit zinc binding,
reducing the tubulin polymerization rate, resulting in a net loss of
polymerized MTs, similar to the effect caused by b-amyloid zinc
sequestration [83]. This could potentially cause memory impair-
ment effects.
Comparison to Aromatic Amino Acids
While the mechanism of general anesthetic action responsible
for erasing conscious awareness is still under debate, quantum
mobility theory posits that anesthetics act by inhibiting signal
propagation between the aromatic amino acids of tubulin [85].
Aromatic amino acids include tyrosine, tryptophan, phenylalanine
and histidine, of which tubulin possesses 35, 8, 43 and 22,
respectively. Numerous sites are near tyrosine residues (sites 11,
12, 16, 21, 22, 24, 32 and 33), phenylalanine residues (sites 4, 15,
16, 24, 25, 28, 32, 41, and 45), and histidine residues (sites 14, 22,
25, 26, 33 and 36) with some lasting for the entire simulation. Of
these, tryptophan is posited to play a prominent role in quantum
mobility theory. The closest predicted site to a tryptophan residue
is site 37, persisting for 100% of the simulation, which is within
5.3 A˚ of bW346. This is consistent with the predictions of
quantum mobility theory.
Experimental Validation
Numerous historical studies give evidence to the interaction
between halothane and tubulin polymerization. The earliest
studies showed concentrations of 2–2.8 % halothane in air by
volume (,0.1 mM) yielded retraction of MT based axopods
suggesting MT depolymerization [41,42]. Consistent results were
found with larger concentrations of halothane. At 10 mM
halothane, MTs were shown to decrease in length and density
[44], and MT based flagellar structures were shortened [46], and
20 mM halothane likewise decreased MT density [45,86].
However, other investigations showed concentrations between 3
and 10 mM increased the number of MTs per area [44,86,87].
Other evidence indicates that halothane concentrations of 10 mM
can produce aberrant MT formations, including ribbon structures
and macrotubules [43,44,88].
This range of behaviors can be attributed to differing
polymerization protocols. Tubulin polymerization is affected by
many factors including pH, temperature and ionic concentrations.
Similar variations in behavior were observed when first charac-
terizing the effect of zinc on tubulin polymerization [89]. By
varying buffer conditions and the ratio of tubulin to zinc,
polymerization ranged from normal to aberrant, with various
intermediate stages.
It is important to note that optical density measurements were
not capable of quantifying polymerization of these zinc induced
aberrant tubulin structures [89]. Optical density measurements
also cannot detect the aberrant assembly of tubulin induced by the
MT destabilizers cryptophycin 1 [90,91,92] and hemiasterlin [90].
The kinetics of MT assembly are often studied by optical density
measurements since the geometry of long thin rods is such that
absorption data is a function of the total mass of the assembled
protein. As such, without knowledge of the shape of tubulin
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aggregates it would be dangerous to interpret absorption data
quantitatively.
In the present study, a halothane concentration of 40 mM
was used to ensure saturation of tubulin by halothane. The
optical density measurements show that in the presence of both
10 mM paclitaxel and 40 mM halothane the optical density
curve is comparable to that of paclitaxel alone within standard
error. This suggests that halothane has no effect on the
interaction between paclitaxel and tubulin, a result consistent
with the computational predictions presented. In the presence of
40 mM halothane alone the optical density curve resembles the
control, however the standard error indicates difference between
the curves with a small increase in the optical density. While
this seems to indicate that halothane does little to modulate
tubulin assembly, previous evidence of altered tubulin structures
and the inability of optical density to quantify such changes
suggest that this may not be the case. Further investigation is
clearly required.
Summary
Anesthetic binding to tubulin may be important for the
mechanism of anesthetic action, and also for anesthetic side
effects related to post-operative cognitive dysfunction and/or
exacerbation of neurodegenerative diseases. The size of the tubulin
macromolecule, its numerous preexisting non-polar, hydrophobic
cavities, and the generally weak binding of volatile anesthetics
hinder the experimental investigation of this molecular mechanism
of interaction. For this reason, it is an important problem to be
able to predict computationally the binding of anesthetics to
tubulin, and of small molecules to proteins in general, although
this is a challenge since binding is often nonspecific, with multiple
binding sites being filled. Thus, we have used a combination of
computational methods including molecular dynamics simula-
tions, surface geometry based anesthetic binding site prediction,
focused and blind docking to identify putative volatile anesthetic
binding sites on, and in, the tubulin protein. We hope that this
work will enable future experiments to resolve the necessary
ambiguity in our computational results.
Multiple binding sites were found on the tubulin protein, but the
availability of these sites for anesthetic binding was found to vary
greatly. Since most binding energies were quite close in value, it is
expected that those with lowest persistence will be filled only at
large anesthetic concentrations.
Since the binding energy of volatile anesthetics in protein
hydrophobic pockets is generally small, the potential for anesthetic
molecules to bind by inducing fits through changes in protein
conformation is extremely low. It is more likely that these
molecules bind in preexisting non-polar, hydrophobic cavities. In
this case destabilization of a protein, or protein structure, may
result either from preferential binding of the anesthetic to a less
stable conformation of the cavity, or the disruption of allosteric
changes at protein interfaces.
We found that favorable thermodynamic conditions for the
binding of anesthetics to tubulin result from van der Waals
interactions. The nine sites predicted to persist for greater than
70% of the 5 ns simulation were located in the binding-pockets
for colchicine, vinblastine, peloruside A, laulimalide, GTP, and
GDP. These sites all reside in regions of either intradimer, or
longitudinal interaction, indicating that at reasonable concentra-
tions anesthetics do not alter lateral interactions. In fact, we do
not predict strong binding in the taxol-binding site, which has
been implicated in lateral interactions. This was also confirmed
by experimental validation within the present investigation.
Our findings suggest that modification of intradimer and
longitudinal interactions may be the general mode of MT
destabilization by volatile anesthetics. This is consistent with
observations that anesthetics are weak destabilizers of MTs under
normal conditions. Steric hindrance caused by the antimitotics
vinblastine and colchicine result in tubulin being constrained to
a curved conformation preventing MT polymerization, and
promoting the formation of macrotubules. At high concentrations
anesthetics are shown to have the same effect, indicating the
possibility of a similar mechanism, thus highlighting these putative
binding sites. Indeed, our prediction of the interference of
halothane with the binding of colchicine to tubulin has already
been confirmed by an experimental study [64].
While anesthetic binding in protein hydrophobic pockets is the
expected mode of interaction, we found comparable binding
energy estimates between the C-tails and the tubulin body
indicating an interaction between halothane and the tubulin C-
termini. Our results show an increase in binding energy with more
surrounding residues of the tail suggesting that halothane may
sequester the C-termini into compact forms. However, solvent
effects are expected to play a prominent role in this interaction and
docking alone cannot provide the detailed energy evaluations
needed to investigate this mechanism. The role of C-termini in
normal MT dynamics, including polymerization, post-translation-
al modification, and interaction with MAPs, marks this potential
interaction as one of interest.
The interaction of volatile anesthetics, including halothane, with
tubulin and MTs is of great interest both for the mechanism of
action of anesthetic gases, and for post-operative cognitive
dysfunction and neurodegenerative diseases that present with
dysfunctional neuronal cytoskeletons [31]. Neurons are unique as
they are non-dividing cells, and thus their MTs are not required to
repeatedly assemble and disassemble as in mitotic spindles. Part of
this is due to the neuronal cytoskeleton, which is highly
architectured and relatively stable. This stability both serves to
prevent division and maintain neuron morphology, which is
essential to overall neural function. Halothane has been shown to
bind to tubulin, alter tubulin polymerization, and disrupt
polymerized MTs [40–47]. This suggests a potential cause of
anesthetic induced exacerbation of neurodegenerative disorders.
In regards to postoperative cognitive dysfunction, our results
suggest that anesthetics may not alter MAP binding directly to
release tau and increase NFT formation. However, altered MT
polymerization, either through the modification of intradimer/
longitudinal contacts, C-terminal tail dynamics, or through effects
on cofactors relevant to polymerization, such as GTP/GDP or
zinc, may result in either net loss of polymerized MTs, or MTs
polymerized into aberrant forms. Due to the overall reduced
number of normal MTs, an excess amount of free tau could arise.
This free tau would be vulnerable to hyper-phosphorylation
leading to an increase in NFT formation. Further investigation
would be required to test these hypotheses.
The role of MTs in cell division marks tubulin as a prominent
chemotherapeutic target. As such there exists the possibility of
adverse drug reactions between volatile anesthetics, cancerous cell
lines and antimitotic agents [93]. Thus, our results may not only
shed light on the role of anesthetics in non-dividing neuron cells,
but also on dividing cells, especially cancer cells, due to the
prominent role of tubulin based MTs in these two classes of cells.
Due to the potential involvement in post-operative cognitive
dysfunction, and the potential adverse drug reactions between
anesthesia and chemotherapy the volatile anesthetic-tubulin
interaction warrants further investigation.
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Methods
Molecular Dynamics (MD) Simulations
Tubulin body. Human tubulin isotypes TUBA4A and
TUBB, being the most prevalent forms in human tissues [94]
were modeled according to previous homology methods [95,96].
Initial set-up was performed in the leap and antechamber modules
of AMBER9 [97–99] using the AMBER03 force field. To obtain
globally minimized structures fifteen high temperature implicitly-
solvated MT dimers were generated at a temperature of 5,000 K
then slowly cooled to a target temperature of 300 K, using steps of
1,000 K over periods of 400 ps, then using a 0.8-power law
cooling-schedule for temperatures below 2000 K. One of the
resulting structures was chosen on which to perform MD
simulations.
MD simulation included two adjacent protofilaments composed
of two tubulin heterodimers. Tubulin dimers were placed in
a configuration consistent with MT geometry [100]. Periodic
boundary conditions were used to model the system as two
periodic protofilaments. The protofilaments were aligned with
their axis parallel to a periodic box of the length of one tubulin
dimer, 81.2 A˚. These were then relaxed for 300 steps without
solvent, and another 300 steps with implicit solvent. Afterwards
the structures were heated to 400 K, and then cooled to 300 K
over a period of 400 ps to obtain further energy minimization.
Na+ ions were added to neutralize the system, and following this
80 Na+ and 80 Cl2 ions were added to bring the ionic
concentration to 100 mM. The system was placed in a periodic
box with dimensions 81.2 A˚ by 107.5 A˚ by 152.5 A˚, filled with
pre-equilibrated explicit TIP3P water using the leap module of
AMBER9 [97–99].
To relieve steric clashes with water the structure was further
energy minimized in GROMACS 3.3.2 [101–103] using 5000
steps of steepest descent, followed by 1000 steps of conjugate
gradient minimization. Following equilibration for 5 ns with a time
step of 2 fs, MD simulation, with periodic boundary conditions at
300 K and constant pressure was performed over a period of
another 5 ns with the same time step. The SHAKE algorithm
[104] was used to constrain bonds involving hydrogen in all
simulations and a non-bonded cutoff of 12 A˚ was used.
Tubulin C-terminal tails. The 1JFF [61] model of tubulin
was repaired with the missing residues of 1TUB [105]. The
repaired 1JFF preparation was performed in the leap module of
AMBER9 [97–99] using the AMBER99SB force field. The
structure was explicitly solvated with TIP3P water in a 25 A˚ box
extending from the protein surface. Thirty-five Na+ ions were
added to neutralize the protein followed by the addition of 107
Na+ and Cl– ions to bring the salt concentration to 100 mM. The
structure was then energy minimized with a conjugate gradient
method using NAMD [106] over 40,000 time steps.
Models of human tubulin isotypes TUBA1A, TUBA1C,
TUBA4A, TUBB, TUBB2A /TUBB2B, TUBB2C, TUBB3,
and TUBB4 were generated using MODELLER [107] 9v6 with
the minimized, repaired 1JFF structure as a template, to produce
50 distinct conformations of each tubulin C-terminal tail.
Volatile Anesthetic Binding Site Prediction
Trajectories from the 5 ns MD simulation were clustered into
dominant conformations of the protein body using the g_cluster
utility of the GROMACS [101–103] 3.3.2 program package
with the single linkage method with 1 A˚ RMSD similarity cut-
off comparing positions of all atoms, with C-terminal tails
excluded. The average structures of the resultant clusters were
subjected to further analysis. Percent simulation (% Simulation)
of the average structures were calculated as the ratio between
the number of timestep snapshots belonging a given cluster
divided by the total number of timesteps in the MD simulation.
Binding sites on the clusters were predicted using the surface
geometry program PASS [51] modified specifically for volatile
anesthetics [49]. The PASS [51] program was run on both the
tubulin dimers in the protofilament conformation, as well as on
each dimer separately to determine if MT geometry affected the
prediction of a site.
Predicted binding sites between clusters were grouped via
a Density Based Spatial Clustering of Applications with Noise
(DBSCAN) [52] method with a minimum group size of 1
predicted site, and nearest neighbor distance of 5 A˚. The center
of each group was taken as the average position of all predicted
sites within a given group. Not all predicted sites were found on all
dominant conformations. Persistence of each site was determined
by taking the sum of the simulation percentages for each of the
dominant conformations on which the site was predicted.
Halothane Docking
Tubulin body. Focused docking runs were performed for
halothane at all predicted sites for the middle structures of all
clusters of tubulin. Halothane geometry was parameterized
according to an ab initio structure calculation [108]. Docking was
performed via AUTODOCK [109] 4.0 using a slow focused
docking protocol [110], and box size of 10 A˚ per and grid spacing
of 0.375 A˚. Binding poses were clustered with a RMSD of 2 A˚.
C-terminal tails. Blind docking runs were performed for
halothane against each of the 50 tail conformations for each
tubulin isotype. Halothane, as parameterized above, was docked
against the C-terminal tails via AUTODOCK [109] 4.0 using
a blind docking protocol [111,112]. Box sizes were adjusted to
accommodate the C-terminal tail conformation with constant grid
spacing of 0.375 A˚. Binding poses were clustered with a RMSD of
2 A˚.
All images were created in PyMOL 0.99rc6 [113].
Microtubule Polymerization Assay
All protein and reagents required for the assay were
purchased from Cytoskeleton Inc. (Denver, CO). 97% pure
lyophilized bovine brain tubulin reconstituted in de-ionized
water (10 mg/ml) was used. 200 ml aliquots were snap frozen in
liquid nitrogen to maintain maximum protein functionality.
Assays were carried out in a 96 well plate. Plates were pre-
warmed at 37uC for 30 min prior to experiment. Using a 95%
ethyl alcohol stock solution halothane (2-Bromo-2-chloro-1,1,1-
trifluoroethane) (Sigma Aldrich, St. Louis, MO) and paclitaxel
(Hospira, Lake Forest, Ill) were prepared to 11 times final
concentration in General Tubulin Buffer (80 mM PIPES,
MgCl2, 0.5 mM EGTA, pH 6.9). The alcohol concentration
of the control was adjusted accordingly. 10 ml of halothane
concentration, General Tubulin Buffer (control), paclitaxel and
paclitaxel with halothane were preheated in separate wells of 96
well plate for 2 min. Immediately before running an assay
tubulin was thawed in 37uC water bath and put on ice. Tubulin
protein was diluted in 450 ml of ice cold Tubulin Polymerization
Buffer (80 mM PIPES, 2 mM MgCl2, 0.5 mM EGTA, pH 6.9,
1 mM GTP 10.2% glycerol). 100 ml of tubulin and polymer-
ization buffer solution were added to each well containing 10 ml
for a final volume of 110 ml. Assay were run for 1 hour at
37uC, with absorbance measurements taken every 30 s at
340 nm using a SPECTROmax 190 (Molecular Devices,
Sunnyvale, CA) plate reader and collected using SOFTmax
Pro version 4.0 software.
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